In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Vanda (VNDA), with a price target of $40. The company’s shares opened today at $19.59.
Archila wrote:
“We believe shares of VNDA should find some relief after the recent volatility (shares down -26% since 2/5 vs. S&P 500 which is up +1%) which has largely been driven by the news of the partial clinical hold (PCH) on tradipitant and the unsealed whistleblower lawsuit, but also the fact VNDA didn’t issue preliminary results at the JP Morgan conference in January which it had normally done in years past. We think the 4Q results and 2019 guidance should get investors more comfortable that VNDA’s base business (Hetlioz and Fanapt) continues to be generally healthy with a decent growth profile.”
According to TipRanks.com, Archila ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -8.6% and a 32.4% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Rhythm Pharmaceuticals Inc, and Selecta Biosciences.
Currently, the analyst consensus on Vanda is a Moderate Buy with an average price target of $37.67.
See today’s analyst top recommended stocks >>
The company has a one-year high of $33.44 and a one-year low of $13.88. Currently, Vanda has an average volume of 874.6K.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051.
